171 related articles for article (PubMed ID: 36483550)
1. Identification of immune-related features involved in Duchenne muscular dystrophy: A bidirectional transcriptome and proteome-driven analysis.
Wu X; Dong N; Yu L; Liu M; Jiang J; Tang T; Zhao H; Fang Q
Front Immunol; 2022; 13():1017423. PubMed ID: 36483550
[TBL] [Abstract][Full Text] [Related]
2. Identification of hub genes, miRNAs and regulatory factors relevant for Duchenne muscular dystrophy by bioinformatics analysis.
Xiu MX; Zeng B; Kuang BH
Int J Neurosci; 2022 Mar; 132(3):296-305. PubMed ID: 32791870
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
4. C-X-C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy.
Lai X; Chen J
Bioengineered; 2021 Dec; 12(1):5428-5439. PubMed ID: 34424816
[TBL] [Abstract][Full Text] [Related]
5. Identifying the hub genes for Duchenne muscular dystrophy and Becker muscular dystrophy by weighted correlation network analysis.
Wang J; Fan Q; Yu T; Zhang Y
BMC Genom Data; 2021 Dec; 22(1):57. PubMed ID: 34922439
[TBL] [Abstract][Full Text] [Related]
6. Identification of hub genes related to Duchenne muscular dystrophy by weighted gene co-expression network analysis.
Wei Y; Su Q; Li X
Medicine (Baltimore); 2022 Dec; 101(52):e32603. PubMed ID: 36596079
[TBL] [Abstract][Full Text] [Related]
7. Identification of hub genes and therapeutic siRNAs to develop novel adjunctive therapy for Duchenne muscular dystrophy.
Li N; Xiahou Z; Li Z; Zhang Z; Song Y; Wang Y
BMC Musculoskelet Disord; 2024 May; 25(1):386. PubMed ID: 38762732
[TBL] [Abstract][Full Text] [Related]
8. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
[TBL] [Abstract][Full Text] [Related]
9. Analysis of Long Noncoding RNAs-Related Regulatory Mechanisms in Duchenne Muscular Dystrophy Using a Disease-Related lncRNA-mRNA Pathway Network.
Xu B; Zheng C
Genet Res (Camb); 2022; 2022():8548804. PubMed ID: 36619896
[TBL] [Abstract][Full Text] [Related]
10. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of Long Non-coding RNA-Associated Competing Endogenous RNA Network in Duchenne Muscular Dystrophy.
Xu X; Hao Y; Xiong S; He Z
Interdiscip Sci; 2020 Dec; 12(4):447-460. PubMed ID: 32876881
[TBL] [Abstract][Full Text] [Related]
12. miR-146a deficiency does not aggravate muscular dystrophy in mdx mice.
Bronisz-Budzyńska I; Chwalenia K; Mucha O; Podkalicka P; Karolina-Bukowska-Strakova ; Józkowicz A; Łoboda A; Kozakowska M; Dulak J
Skelet Muscle; 2019 Aug; 9(1):22. PubMed ID: 31412923
[TBL] [Abstract][Full Text] [Related]
13. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia.
Greco S; De Simone M; Colussi C; Zaccagnini G; Fasanaro P; Pescatori M; Cardani R; Perbellini R; Isaia E; Sale P; Meola G; Capogrossi MC; Gaetano C; Martelli F
FASEB J; 2009 Oct; 23(10):3335-46. PubMed ID: 19528256
[TBL] [Abstract][Full Text] [Related]
14. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
[TBL] [Abstract][Full Text] [Related]
15. Serum miR-206 and other muscle-specific microRNAs as non-invasive biomarkers for Duchenne muscular dystrophy.
Hu J; Kong M; Ye Y; Hong S; Cheng L; Jiang L
J Neurochem; 2014 Jun; 129(5):877-83. PubMed ID: 24460924
[TBL] [Abstract][Full Text] [Related]
16. Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in Golden Retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients.
Jeanson-Leh L; Lameth J; Krimi S; Buisset J; Amor F; Le Guiner C; Barthélémy I; Servais L; Blot S; Voit T; Israeli D
Am J Pathol; 2014 Nov; 184(11):2885-98. PubMed ID: 25194663
[TBL] [Abstract][Full Text] [Related]
17. Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.
Coenen-Stass AM; McClorey G; Manzano R; Betts CA; Blain A; Saleh AF; Gait MJ; Lochmüller H; Wood MJ; Roberts TC
Sci Rep; 2015 Nov; 5():17014. PubMed ID: 26594036
[TBL] [Abstract][Full Text] [Related]
18. miR-378 affects metabolic disturbances in the mdx model of Duchenne muscular dystrophy.
Podkalicka P; Mucha O; Kaziród K; Szade K; Stępniewski J; Ivanishchuk L; Hirao H; Pośpiech E; Józkowicz A; Kupiec-Weglinski JW; Dulak J; Łoboda A
Sci Rep; 2022 Mar; 12(1):3945. PubMed ID: 35273230
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
20. Cardiomyocyte-produced miR-339-5p mediates pathology in Duchenne muscular dystrophy cardiomyopathy.
Gartz M; Beatka M; Prom MJ; Strande JL; Lawlor MW
Hum Mol Genet; 2021 Nov; 30(23):2347-2361. PubMed ID: 34270708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
